Trial
ORATORIO
Ocrelizumab vs placebo in primary progressive multiple sclerosis (PPMS).
Also called: ocrelizumab PPMS trial
In short
- 1What it is: a trial in therapies and applications.
- 2How it connects: acts on 1 and is affected by 1 concepts — mostly 2 therapy.
- 3Where it sits: trial on the 15-step immune chain.
What it does
24% slower CDP (HR 0.76, p=0.003).
Its connections at a glance
Each dot is a concept directly linked to ORATORIO. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID TR007 · concept status: established. Select any connection above to inspect evidence for that specific link.